Using prasugrel (Effient) alone in the first month after PCI did not reduce bleeding risk and there was a suggestion of possible increased ischemic risk vs dual antiplatelet therapy, in a new trial.
SAGA Fearing that a lack of higher educational institutions is causing a “brain drain,” Saga prefectural officials are seeking to open new universities and reorganize an existing one.
Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not superior to dual-antiplatelet therapy (DAPT) for major bleeding but is non-inferior for cardiovascular events in patients with acute coronary syndrome (ACS) or high bleeding risk (HBR), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.